3-氟苯基甲烷磺酰氯 | 24974-72-9

• 物质功能分类: 化学试剂 - 有机试剂 - 磺酸盐/亚磺酸盐
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-氟苯基甲烷磺酰氯
• 中文别名: 3-氟苯甲磺酰氯
• 英文名称: (3-fluorophenyl)methanesulfonyl chloride
• 英文别名: (3-fluorophenyl)methanesulphonyl chloride
• CAS: 24974-72-9
• 化学式: C₇H₆ClFO₂S
• mdl: MFCD04117456
• 分子量: 208.641
• InChiKey: QKGIPEQAFOXGSI-UHFFFAOYSA-N

物化性质

• 熔点：
  39 °C
• 沸点：
  285.9±23.0 °C(Predicted)
• 密度：
  1.465±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  42.5
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi,C
• 危险类别码：
  R22

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: (3-Fluorophenyl)methanesulfonyl chloride
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: (3-Fluorophenyl)methanesulfonyl chloride
CAS number: 24974-72-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H6ClFO2S
Molecular weight: 208.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen chloride, hydrogen fluoride, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

3-氟苯基甲烷磺酰氯可用作医药合成中间体。若吸入该物质，请将患者移至新鲜空气处；如皮肤接触，脱去污染衣物，并用肥皂水和清水彻底清洗皮肤；如有不适，请及时就医；眼睛接触时，分开眼睑，用流动清水或生理盐水冲洗，并立即寻求医疗帮助；若误食，应立即漱口，禁止催吐，并尽快就医。

反应信息

• 作为反应物：
  描述：

  3-氟苯基甲烷磺酰氯 在 ammonium hydroxide 、 碳酸氢铵 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 以1.5 g的产率得到(3-fluorophenyl)methanesulfonamide
  参考文献：
  名称：

  P2Y12拮抗剂乙基6-（4-（（苯甲磺酰基）氨基甲酰基）哌啶-1-基）-5-氰基-2-甲基烟酸酯（AZD1283）的优化导致发现具有改善的类药物特性的口服抗血小板药。

  摘要：

  P2Y12拮抗剂广泛用作预防和治疗动脉血栓形成的抗血小板药。基于已知的P2Y12拮抗剂AZD1283的支架，设计和合成了一系列新型的双环吡啶衍生物。吡啶环上的酯取代基与邻甲基的环化作用导致AZD1283的内酯类似物在随后的结构-药代动力学关系研究中显示出显着增强的代谢稳定性。通过向哌啶基部分添加4-甲基取代基进一步增强了代谢稳定性。在大鼠氯化铁模型中，化合物58l在体外显示出对血小板聚集的有效抑制以及抗血栓形成的功效。而且，58l显示出的安全性优于在大鼠尾巴出血模型中观察到的氯吡格雷的安全性。这些结果支持进一步评价化合物58l作为有前途的候选药物。

  DOI：

  10.1021/acs.jmedchem.8b01971
• 作为产物：
  描述：

  间氟氯苄 在 盐酸 、 N-氯代丁二酰亚胺 作用下， 以 乙醇 、 水 、 乙腈 为溶剂， 反应 1.5h， 生成 3-氟苯基甲烷磺酰氯
  参考文献：
  名称：

  通过增强疏水相互作用作为有效的 c-Met 抑制剂的磺酰脒的设计、合成和生物学评价

  摘要：

  c-Met 激酶失调已成为各种人类癌症发生、进展、不良临床结果和耐药性的重要因素。在我们不断寻找有前途的 c-Met 抑制剂作为潜在抗肿瘤药物的过程中，之前报道的 c-Met 抑制剂7的对接研究揭示了一个大的未占据的疏水口袋，这可能为进一步探索结构-活性关系以改善与 c-Met 变构疏水后袋的结合亲和力。在此，我们基于先导化合物7进行了构效关系和分子建模研究。集体努力最终发现了化合物21j ，通过增加与 c-Met 活性位点疏水性后袋的疏水相互作用，其功效优于7和阳性对照 foretinib。

  DOI：

  10.1039/d3ob01156a

文献信息

• Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
  申请人：F. HOFFMANN-LA ROCHE LTD

  公开号：US20130102600A1

  公开（公告）日：2013-04-25

  The present invention relates to a compound having the general formula I, optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which is useful in treating, ameliorating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.

  本发明涉及一种具有通式I的化合物，可选地以药物可接受的盐、溶剂化物、多晶型、前药、互变异构体、外消旋体、对映体、非对映体或其混合物的形式，该化合物在治疗、改善或预防病毒性疾病方面有用。此外，还公开了特定的组合疗法。
• Nitromethylthiobenzene derivatives as inhibitors of aldose reductase
  申请人：Merck PatentGesellschaft mit

  公开号：US06509499B1

  公开（公告）日：2003-01-21

  The invention concerns novel compound of general formula (1) in which: P, T1, T2, X and n are as defined in claim 1, their tautomeric forms, and their additive salts with pharmaceutically acceptable bases. The invention also concerns methods for preparing these compounds and their applications as medicines. These compounds inhibit the aldose reductase enzyme and can be used in the treatment or prevention of peripheral and autonomous neurological diabetic complications, renal and ocular disorders such as cataract and retinopathy.

  本发明涉及一种通用公式（1）的新化合物，其中：P、T1、T2、X和n定义如权利要求1所述，它们的互变异构体，以及它们与药用可接受碱的可加性盐。本发明还涉及制备这些化合物的方法及其作为药物的应用。这些化合物抑制aldose还原酶酶，可用于治疗或预防周围性和自主性神经糖尿病并发症、肾脏和眼科疾病，如白内障和视网膜病变。
• Alkyne Linchpin Strategy for Drug:Pharmacophore Conjugation: Experimental and Computational Realization of a <i>Meta</i>-Selective Inverse Sonogashira Coupling
  作者：Sandip Porey、Xinglong Zhang、Suman Bhowmick、Vikas Kumar Singh、Srimanta Guin、Robert S. Paton、Debabrata Maiti

  DOI：10.1021/jacs.9b10646

  日期：2020.2.26

  with sp3-rich 3D-fragments and natural products. This is accomplished through a template-assisted inverse Sonogashira reaction that displays high levels of selectivity for the meta-position. This protocol is also amenable to distal structural modifications of α-amino acids. The transformation of alkyne functionality to other functional groups further highlights the applicative potential. Computational

  通过 CH 键的位点选择性激活，药物和农用化学化合物的后期功能化 (LSF) 提供了对各种结构类似物的直接访问，并扩大了可访问的化学空间。我们报告了一种 CH 功能化 LSF 策略，该策略取决于使用炔关键销来组装富含 sp2 的市售药物和农用化学品与富含 sp3 的 3D 片段和天然产物的结合物。这是通过模板辅助的逆 Sonogashira 反应实现的，该反应对间位具有高水平的选择性。该协议也适用于 α-氨基酸的远端结构修改。炔官能团向其他官能团的转化进一步突出了应用潜力。计算和实验机制研究阐明了详细的机制。溴炔偶联伙伴的转换限制 1,2-迁移插入发生在相对快速的 CH 激活之后。虽然这种插入是非选择性发生的，但区域会聚是由于加合物之一经历 1,2-三烷基甲硅烷基迁移以形成炔化产物。对产物形成必不可少的异质双金属 Pd-Ag TS 明确涉及 β-溴化物消除步骤。
• THIAZOLIDINONE COMPOUNDS AND USE THEREOF
  申请人：National Health Research Institutes

  公开号：US20170253569A1

  公开（公告）日：2017-09-07

  A pharmaceutical composition containing a compound of Formula (I) for treating an opioid receptor-associated condition. Also disclosed is a method for treating an opioid receptor-associated condition using such a compound. Further disclosed are two sets of thiazolidinone compounds of formula (I): (i) compounds each having an enantiomeric excess greater than 90% and (ii) compounds each being substituted with deuterium.

  一种含有化合物（I）的药物组合物，用于治疗与阿片受体相关的疾病。还公开了一种使用这种化合物治疗阿片受体相关疾病的方法。进一步公开了两组式（I）的噻唑烷酮化合物：（i）每种化合物的对映体过量大于90%；（ii）每种化合物被氘取代。
• 一种具有高口服生物利用度的JAK抑制剂
  申请人：嘉兴特科罗生物科技有限公司

  公开号：CN113603677B

  公开（公告）日：2022-06-14

  本发明提供了一种具有高口服生物利用度的JAK抑制剂，其特征在于，所述JAK抑制剂包含如下的式I化合物，或其立体异构体、几何异构体、互变异构体、水合物、溶剂化物、以及药学上可接受的盐作为活性成分。本发明提供的具有高口服生物利用度的JAK抑制剂能够克服现有的JAK抑制剂口服生物利用度低的障碍，通过进一步化合物修饰以改变一类或几类小分子化合物的物理化学特性，从而提高该类化合物的体内细胞吸收性能，极大提高药物的生物利用度，也对该类化合物药物的给药方式及使用提供了新的可能。